Clinical Investigation of the Freedom SOLO Stentless Heart Valve
This study is ongoing, but not recruiting participants.
Sponsor:
Sorin Group
Information provided by (Responsible Party):
Sorin Group
ClinicalTrials.gov Identifier:
NCT00876525
First received: April 3, 2009
Last updated: September 5, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a trial to demonstrate the safety and effectiveness of the Freedom SOLO heart valve when used to replace a diseased or dysfunctional aortic valve or aortic valve prosthesis.
| Condition | Intervention |
|---|---|
|
Heart Valve Diseases |
Device: Freedom SOLO |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Clinical Investigation of the Freedom SOLO Stentless Heart Valve |
Resource links provided by NLM:
Genetics Home Reference related topics:
supravalvular aortic stenosis
Drug Information available for:
Diazepam
U.S. FDA Resources
Further study details as provided by Sorin Group:
Primary Outcome Measures:
- The complication and survival rates for the Freedom SOLO stentless valve. [ Time Frame: Preoperatively, at implant, early postoperative, late postoperative, 1 year, annually until study completion. ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Hemodynamic performance of the Freedom SOLO stentless valve. Clinically significant improvement in overall patient condition. [ Time Frame: Preoperatively, at implant, early postoperative, late postoperative, 1 year, annually until study completion. ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 700 |
| Study Start Date: | March 2009 |
| Estimated Study Completion Date: | September 2017 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Freedom SOLO stentless valve |
Device: Freedom SOLO
The Freedom SOLO heart valve prosthesis is a stentless bioprosthesis manufactured with bovine pericardium.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- The patient is male or female 18 years old or older.
- The patient is willing to sign the informed consent.
- The patient which preoperative evaluation indicated the need for native or prosthetic aortic valve replacement.
- Any patient amenable to aortic valve replacement with biological prosthesis should be enrolled in the study, even in conjunction with valve repair, coronary artery bypass grafting and other procedures.
- The patient is located in a geographic location that will enable the subject to return to the study site for all follow-up examinations (i.e. geographically stable).
- Patient will be available to the investigator(s) for postoperative follow-up beyond one year.
Exclusion Criteria:
- The patient has preexisting valve prosthesis in the mitral, pulmonary or tricuspid position.
- The patient requires a double or triple valve replacement (a valve repair is not considered an exclusion criterion).
- The patient has a previously implanted SOLO valve, within the clinical study, that requires replacement.
- The patient has active endocarditis.
- The patient is or will be participating in a concomitant research study of an investigational product.
- The patient is a minor, intravenous drug user, alcohol abuser, prisoner, institutionalized, or is unable to give informed consent.
- The patient has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the patient.
- The patient is pregnant or lactating.
- Patients with congenital bicuspid aortic valve.
- Patients are known to be noncompliant or are unlikely to complete the study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00876525
Locations
| Austria | |
| Krankenhaus Hietzing | |
| Wien, Austria, 1030 | |
| Medical University Vienna | |
| Wien, Austria, 1090 | |
| Belgium | |
| St. Luc Hospital | |
| Bruxelles, Belgium, 1200 | |
| University Hospital Gent | |
| Gent, Belgium, 9000 | |
| France | |
| Hôpital Pontchaillou - CHU | |
| Rennes, France, 35033 | |
| Hôpital Trousseau - CHRU | |
| Tours, France, 37000 | |
| Germany | |
| Herz- und Gefäß-Klinik GmbH | |
| Bad Neustadt, Germany, 97616 | |
| Charité Hospital | |
| Berlin, Germany, 10117 | |
| Herzzentrum Dresden Universitätsklinik an der Technischen Universität Dresden | |
| Dresden, Germany, 01307 | |
| Universitätsklinikum Erlangen, Klinik für Herzchirurgie | |
| Erlangen, Germany, 91054 | |
| Italy | |
| Ospedale del Cuore, Fondazione G. Monasterio | |
| Massa, Italy, 54100 | |
| Ospedale "S. Maria di Ca' Foncello" | |
| Treviso, Italy, 31100 | |
| Ospedale S. Maria Della Misericordia | |
| Udine, Italy, 33100 | |
| Netherlands | |
| Academisch Medisch Centrum | |
| Amsterdam, Netherlands, 1100 DD | |
| Catharina Hospital | |
| Eindhoven, Netherlands, 5623 EJ | |
| Medisch Spectrum Twente, Thoraxcentrum | |
| Enschede, Netherlands, 7513 ER | |
| University Hospital St. Radboud | |
| Nÿmegen, Netherlands, 6500 HB | |
| Portugal | |
| Hospital S. João | |
| Porto, Portugal, 4200-319 | |
| Switzerland | |
| Inselspital, University Hospital Berne | |
| Bern, Switzerland, 3010 | |
Sponsors and Collaborators
Sorin Group
Investigators
| Principal Investigator: | Markus Thalmann, MD | KH Hietzing Wien |
More Information
No publications provided
| Responsible Party: | Sorin Group |
| ClinicalTrials.gov Identifier: | NCT00876525 History of Changes |
| Other Study ID Numbers: | V10604 |
| Study First Received: | April 3, 2009 |
| Last Updated: | September 5, 2012 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Netherlands: Dutch Health Care Inspectorate Portugal: National Pharmacy and Medicines Institute |
Keywords provided by Sorin Group:
|
Heart diseases. Aortic valve diseases. Aortic valve insufficiency. Aortic valve stenosis. |
Additional relevant MeSH terms:
|
Heart Valve Diseases Heart Diseases Cardiovascular Diseases Diazepam Anticonvulsants Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Hypnotics and Sedatives |
Central Nervous System Depressants Muscle Relaxants, Central Neuromuscular Agents Anti-Anxiety Agents Tranquilizing Agents Psychotropic Drugs Anesthetics, Intravenous Anesthetics, General Anesthetics GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adjuvants, Anesthesia |
ClinicalTrials.gov processed this record on May 21, 2013